SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for BVNRY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical SG&A Expense (TTM) Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 218.74M
March 31, 2026 207.02M
December 31, 2025 194.31M
September 30, 2025 186.98M
June 30, 2025 154.59M
March 31, 2025 151.95M
December 31, 2024 147.16M
September 30, 2024 135.21M
June 30, 2024 132.91M
March 31, 2024 134.60M
December 31, 2023 126.64M
September 30, 2023 117.75M
June 30, 2023 105.23M
March 31, 2023 88.02M
December 31, 2022 82.92M
September 30, 2022 73.93M
June 30, 2022 73.10M
March 31, 2022 74.45M
December 31, 2021 77.13M
September 30, 2021 80.75M
June 30, 2021 86.78M
March 31, 2021 87.80M
December 31, 2020 86.38M
September 30, 2020 73.45M
June 30, 2020 58.86M
Date Value
March 31, 2020 45.03M
December 31, 2019 33.99M
September 30, 2019 32.78M
June 30, 2019 32.20M
March 31, 2019 33.42M
December 31, 2018 33.83M
September 30, 2018 34.73M
June 30, 2018 33.85M
March 31, 2018 32.65M
December 31, 2017 31.88M
September 30, 2017 30.66M
June 30, 2017 31.39M
March 31, 2017 31.13M
December 31, 2016 31.60M
September 30, 2016 32.10M
June 30, 2016 30.42M
March 31, 2016 30.28M
December 31, 2015 32.28M
September 30, 2015 35.54M
June 30, 2015 39.44M
March 31, 2015 40.83M
December 31, 2014 40.08M
September 30, 2014 39.29M
June 30, 2014 37.59M
March 31, 2014 36.45M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Evaxion AS 4.527M
Genmab A/S 726.50M
Ascendis Pharma A/S 662.10M
Zealand Pharma A/S 78.53M
Agenus, Inc. 38.48M